DK2101799T3 - Anvendelse af anaboliske midler, anti-kataboliske midler, antioxidantsmidler og analgetika til beskyttelse, behandling og gendannelse af bindevæv i mennesker og dyr - Google Patents

Anvendelse af anaboliske midler, anti-kataboliske midler, antioxidantsmidler og analgetika til beskyttelse, behandling og gendannelse af bindevæv i mennesker og dyr Download PDF

Info

Publication number
DK2101799T3
DK2101799T3 DK07862507.6T DK07862507T DK2101799T3 DK 2101799 T3 DK2101799 T3 DK 2101799T3 DK 07862507 T DK07862507 T DK 07862507T DK 2101799 T3 DK2101799 T3 DK 2101799T3
Authority
DK
Denmark
Prior art keywords
use according
glucosamine
asu
agents
inflammation
Prior art date
Application number
DK07862507.6T
Other languages
English (en)
Inventor
Todd R Henderson
Carmelita Frondoza
Original Assignee
Nutramax Lab Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Nutramax Lab Inc filed Critical Nutramax Lab Inc
Application granted granted Critical
Publication of DK2101799T3 publication Critical patent/DK2101799T3/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7008—Compounds having an amino group directly attached to a carbon atom of the saccharide radical, e.g. D-galactosamine, ranimustine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/737—Sulfated polysaccharides, e.g. chondroitin sulfate, dermatan sulfate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/48—Fabaceae or Leguminosae (Pea or Legume family); Caesalpiniaceae; Mimosaceae; Papilionaceae
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/54—Lauraceae (Laurel family), e.g. cinnamon or sassafras
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/04—Drugs for skeletal disorders for non-specific disorders of the connective tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Natural Medicines & Medicinal Plants (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Molecular Biology (AREA)
  • Mycology (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Alternative & Traditional Medicine (AREA)
  • Biotechnology (AREA)
  • Botany (AREA)
  • Medical Informatics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Dermatology (AREA)
  • Biomedical Technology (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Claims (17)

1. Anvendelse af en kombination omfattende en eller flere uforsæbelige bestanddele af avocado/sojabønne, et aminosukker og en glycosaminoglycan-komponent til fremstilling af et medikament til forebyggelse og/eller behandling af en inflammation associeret med beskadigelse af bindevæv i mennesker og dyr.
2. Anvendelse ifølge krav 1, hvor medikamentet skal indgives dagligt for at opnå en ligevægtskoncentration i en kropsvæske af mennesket eller dyret, som bader en target-celletype, der påvirker mindst en af COX-2, TNF-α, IL-1β, iNOS, p38 og kemokiner, og hvor doseringen derefter reduceres i mindst en af frekvens og mængde for at bibeholde en ønsket reaktion i mennesket eller dyret.
3. Anvendelse ifølge krav 1, hvor aminosukkeret er glucosamin, og glycosa-minoglycan-komponenten er chondroitinsulfat, og hvor medikamentet skal indgives i target-mennesket eller -dyret for at forebygge og/eller behandle en inflammation i en mængde, som er virksom med henblik på at moderere genekspressionen af mindst en af COX-2, TNF-α, IL-1 β, iNOS, p38 og kemokiner til tilnærmelsesvis normale værdier.
4. Anvendelse ifølge krav 1, hvor medikamentet reducerer PGE-2-niveauer eller hæmmer eller nedregulerer en genekspression af COX-2, TNF-α, IL-1 β, iNOS, p38 eller kemokiner i en vævscelle.
5. Anvendelse ifølge krav 4, hvor vævscellen er udvalgt fra gruppen bestående af: chondrocyter, makrofag, monocyter og fibroblaster.
6. Anvendelse ifølge krav 4, hvor medikamentet desuden omfatter methylsul-fonylmethan.
7. Anvendelse ifølge krav 4, hvor den ene eller flere uforsæbelige bestanddele af avocado/sojabønne omfatter en eller flere phytosteroler.
8. Anvendelse ifølge krav 7, hvor phytosterolerne er udvalgt fra gruppen bestående af campesterol, stigmasterol, dihydro-brassisterol og beta-sitosterol.
9. Anvendelse ifølge krav 4, hvor aminosukkeret er naturligt, syntetisk eller halvsyntetisk.
10. Anvendelse ifølge krav 4, hvor den ene eller flere uforsæbelige bestanddele af avocado/sojabønne er naturlige, syntetiske eller halvsyntetiske.
11. Anvendelse ifølge krav 4, hvor aminosukkeret er blevet kemisk modificeret via en eller flere af esterificering, sulfatering, polysulfatering, acetylering og methylering.
12. Anvendelse ifølge krav 4, hvor aminosukkeret er udvalgt fra gruppen bestående af glucosamin, glucosaminsalte og blandinger deraf.
13. Anvendelse ifølge krav 4, hvor aminosukkeret er udvalgt fra gruppen bestående af glucosaminhydrochlorid, glucosaminsulfat, glucosaminphosphat, mannosamin og salte af N-acetylglucosamin.
14. Anvendelse ifølge krav 4, hvor glycosaminoglycan-komponenten er en naturlig, syntetisk eller halvsyntetisk glycosaminoglycan, em glycosami-noglycan-lignende forbindelse, en glycosaminoglycan-precursor eller fragmenter af en glycosaminoglycan.
15. Anvendelse ifølge krav 4, hvor glycosaminoglycan-komponenten er blevet kemisk modificeret via en eller flere af esterificering, sulfatering, polysul-fatering, acetylering og methylering.
16. Anvendelse ifølge krav 4, hvor glycosaminoglycan-komponenten er udvalgt fra gruppen bestående af chondroitin, chondroitinsalte, hyaluronsyre, pentosanpolysulfat og blandinger deraf.
17. Anvendelse ifølge krav 4, hvor glycosaminoglycan-komponenten er chondroitinsulfat.
DK07862507.6T 2006-12-06 2007-12-05 Anvendelse af anaboliske midler, anti-kataboliske midler, antioxidantsmidler og analgetika til beskyttelse, behandling og gendannelse af bindevæv i mennesker og dyr DK2101799T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US11/634,383 US20070141181A1 (en) 1998-02-13 2006-12-06 Use of anabolic agents, anti-catabolic agents, antioxidant agents, and analgesics for protection, treatment and repair of connective tissues in humans and animals
PCT/US2007/024853 WO2008070086A2 (en) 2006-12-06 2007-12-05 A composition for treatment of connective tissues

Publications (1)

Publication Number Publication Date
DK2101799T3 true DK2101799T3 (da) 2015-04-07

Family

ID=39492846

Family Applications (1)

Application Number Title Priority Date Filing Date
DK07862507.6T DK2101799T3 (da) 2006-12-06 2007-12-05 Anvendelse af anaboliske midler, anti-kataboliske midler, antioxidantsmidler og analgetika til beskyttelse, behandling og gendannelse af bindevæv i mennesker og dyr

Country Status (12)

Country Link
US (2) US20070141181A1 (da)
EP (1) EP2101799B1 (da)
JP (1) JP5606071B2 (da)
AU (1) AU2007328265B2 (da)
CA (1) CA2672108C (da)
DK (1) DK2101799T3 (da)
ES (1) ES2535213T3 (da)
HK (1) HK1136202A1 (da)
NZ (1) NZ577602A (da)
PL (1) PL2101799T3 (da)
PT (1) PT2101799E (da)
WO (1) WO2008070086A2 (da)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101547688A (zh) * 2006-09-19 2009-09-30 惠氏公司 Lxr激动剂用于治疗骨关节炎的用途
EP2156842A4 (en) 2007-06-01 2013-01-23 Kyowa Hakko Bio Co Ltd ORAL COMPOSITION
ES2325392B1 (es) * 2007-12-28 2010-06-24 Bioiberica, S.A. Composicion para el tratamiento de la artrosis.
WO2010017403A2 (en) * 2008-08-06 2010-02-11 Immunopath Profile, Inc. Therapeutic compositions, devices and methods for observing treated tissues
US20110213236A1 (en) * 2008-08-06 2011-09-01 Immunopath Profile, Inc. Therapeutic compositions, devices and methods for observing treated tissues
WO2010088378A1 (en) * 2009-01-29 2010-08-05 Levine Joshua D Method of adding botanical agents/dietary supplements to pharmaceutical agents in a pharmacotherapeutic regimen
US20160030530A1 (en) * 2013-03-15 2016-02-04 Nutramax Laboratories, Inc. Sulforaphane/sulforaphane precursor and phytosterol/phytostanol compositions
US10548937B2 (en) * 2014-08-20 2020-02-04 Kolinpharma S.P.A. Composition for the treatment of arthropathies and osteoarthritis
KR101972691B1 (ko) * 2015-04-08 2019-04-25 마이크로바스쿨라 헬스 솔루션즈, 엘엘씨 상승적인 글리코칼릭스 치료 조성물 및 방법
EP3586851A1 (en) 2018-06-27 2020-01-01 Nextraresearch S.r.l. Compositions for oral administration of pentosan polysulfate and chitosan in form of nanoparticles with improved intestinal absorption

Family Cites Families (49)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2281173A (en) 1940-01-10 1942-04-28 Victor Insulators Inc Insulator and method of producing conducting coating thereon
US2881173A (en) * 1957-02-14 1959-04-07 Hoffmann La Roche Basic ethers of hydroxy anthraquinones
US3887700A (en) * 1969-11-28 1975-06-03 Aspro Nicholas Ltd Analgesic formulations
BE759520A (fr) * 1969-11-28 1971-04-30 Aspro Nicholas Ltd Compositions d'aspirine
US3624114A (en) * 1969-12-18 1971-11-30 Jean V Morelle Fatty acid amido-methionine products
US3993756A (en) * 1973-05-09 1976-11-23 Takashi Kaneda Antilipemic agent containing a soybean oil fraction
GB1511302A (en) * 1974-04-15 1978-05-17 Univ Johns Hopkins Pharmaceutical compositions comprising amino acid analogues
GB1506563A (en) * 1974-04-25 1978-04-05 Williams J Immunosuppressive agents
DE2967049D1 (en) * 1978-04-11 1984-07-19 Efamol Ltd Pharmaceutical and dietary composition comprising gamma-linolenic acids
US4333484A (en) * 1978-08-02 1982-06-08 Philip Morris Incorporated Modified cellulosic smoking material and method for its preparation
US4296127A (en) * 1979-04-18 1981-10-20 The Johns Hopkins University Mixed salts of essential or semi-essential amino acids and nitrogen-free analogs thereof
US4314989A (en) * 1980-05-07 1982-02-09 Rosen Gerald M Methionine sulfoxide amflioration of acetaminophen toxicity
US4386072A (en) * 1981-06-26 1983-05-31 Horrobin David F Treatment of disorders of inflammation and immunity and disorders associated with smooth muscle spasm and compositions therefor
FR2543145B1 (fr) * 1983-03-24 1986-10-17 Sanofi Sa Nouveaux sulfates de xylanes, leur procede de preparation et leur activite anti-thrombotique et hypolipemiante
JPS59187792A (ja) * 1983-04-11 1984-10-24 Meito Sangyo Kk 酵素法リン脂質糖類誘導体の製法
US4925833A (en) * 1983-12-29 1990-05-15 The Research Foundation Of State University Of New York Use of tetracycline to enhance bone protein synthesis and/or treatment of osteoporosis
US5225192A (en) * 1988-10-17 1993-07-06 Vectorpharma International S.P.A. Poorly soluble medicaments supported on polymer substances in a form suitable for increasing their dissolving rate
US5569469A (en) * 1984-10-16 1996-10-29 Vectorpharma International, S.P.A. Poorly soluble medicaments supported on polymer substances in a form suitable for increasing their dissolving rate
FR2572731B1 (fr) * 1984-11-07 1987-03-06 Sanofi Sa Nouveaux sulfates de xylanes de bas poids moleculaires, leur procede de preparation et leur activite antithrombotique et hypolipemiante par voie orale
US4683298A (en) * 1985-01-10 1987-07-28 British Columbia Research Council Process for the preparation of aminated polysaccharide derivatives
US4900724A (en) * 1985-03-04 1990-02-13 Sawai Pharmaceutical Co., Ltd Tumor necrosis factor inducing substance derived from acid-fast bacteria
KR890001236B1 (ko) * 1985-10-02 1989-04-28 화이자 인코포레이티드 소염제 조성물의 제조방법
GB8621816D0 (en) * 1986-09-10 1986-10-15 Efamol Ltd Therapeutic composition
CA1327354C (en) 1987-03-19 1994-03-01 David Cullis-Hill Anti-inflamatory compounds and compositions
GB2223943A (en) 1988-10-21 1990-04-25 Tillotts Pharma Ag Oral disage forms of omega-3 polyunsaturated acids
IT1227626B (it) * 1988-11-28 1991-04-23 Vectorpharma Int Farmaci supportati aventi velocita' di dissoluzione aumentata e procedimento per la loro preparazione
US5084482A (en) * 1990-04-10 1992-01-28 The Lithox Corporation Methods for inhibiting inflammatory ischemic, thrombotic and cholesterolemic disease response with methionine compounds
US5137712A (en) * 1990-08-31 1992-08-11 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Use of s-adenosyl-l-methionine (SAMe) to reverse and/or prevent supersensitivity, tolerance and extrapyramidal side effects induced by neuroleptic treatment
FR2671725B1 (fr) * 1991-01-23 1995-06-02 Coletica Complexe de polyose et d'acide gras, utilisation comme agent emulsionnant ou hydratant et composition emulsionnante ou hydratante en contenant.
US5658767A (en) * 1991-01-24 1997-08-19 Martek Corporation Arachidonic acid and methods for the production and use thereof
FR2678632B1 (fr) * 1991-07-03 1994-09-02 Pharmascience Lab Procede de preparation de l'insaponifiable d'avocat permettant d'ameliorer sa teneur en l'une de ses fractions dite h.
US5770209A (en) * 1991-08-30 1998-06-23 University Of South Florida Acceleration of wound healing using connective tissue growth factor
US5215759A (en) * 1991-10-01 1993-06-01 Chanel, Inc. Cosmetic composition
US5260066A (en) * 1992-01-16 1993-11-09 Srchem Incorporated Cryogel bandage containing therapeutic agent
CA2090743A1 (en) * 1992-02-28 1993-08-29 Michael Brunavs Pharmaceutical compounds
US5258371A (en) * 1992-05-29 1993-11-02 Kuraray Co., Ltd. Method to reduce connective tissue destruction
US5474757A (en) * 1992-10-16 1995-12-12 Rutgers University Prevention of acetaminophen overdose toxicity with organosulfur compounds
AU683027B2 (en) 1993-01-27 1997-10-30 Scotia Holdings Plc Triglycerides
US5354853A (en) * 1993-03-12 1994-10-11 Genzyme Corporation Phospholipid-saccharide conjugates
US5364845C1 (en) * 1993-03-31 2002-09-10 Nutramax Lab Inc Glusosamine chondroitin and manganese composition for the protection and repair of connective tissue
EP0693086A1 (en) * 1993-04-07 1996-01-24 Alko Group Ltd. Applications and methods for the preparation of fatty acid esters of polysaccharides
IT1264545B1 (it) * 1993-07-30 1996-10-02 Medidom Lab Procedimento per la preparazione della diacereina
US5411988A (en) * 1993-10-27 1995-05-02 Bockow; Barry I. Compositions and methods for inhibiting inflammation and adhesion formation
GB9417102D0 (en) * 1994-08-24 1994-10-12 Lilly Industries Ltd Pharmaceutical compounds
US5891465A (en) * 1996-05-14 1999-04-06 Biozone Laboratories, Inc. Delivery of biologically active material in a liposomal formulation for administration into the mouth
US5843919A (en) * 1996-11-25 1998-12-01 Burger; John A. Composition and method for the treatment of arthritis
US6451771B1 (en) * 1999-02-12 2002-09-17 Nutramax Laboratories, Inc. Use of anabolic agents anti-catabolic agents and antioxidant agents for protection treatment and repair of connective tissues in humans and animals
US6797289B2 (en) * 1998-02-13 2004-09-28 Nutramax Laboratories, Inc. Use of anabolic agents, anti-catabolic agents, antioxidant agents, and analgesics for protection, treatment and repair of connective tissues in humans and animals
DK1227826T3 (da) * 1999-07-06 2004-01-12 Foodscience Corp Sammensætninger omfattende et ekstrakt af Perna canaliculus, methylsulfonylmethan og glucosamid samt anvendelsen heraf

Also Published As

Publication number Publication date
WO2008070086A2 (en) 2008-06-12
WO2008070086A3 (en) 2008-11-27
NZ577602A (en) 2012-10-26
ES2535213T3 (es) 2015-05-06
JP5606071B2 (ja) 2014-10-15
US20100203177A1 (en) 2010-08-12
PL2101799T3 (pl) 2015-06-30
EP2101799B1 (en) 2015-01-21
EP2101799A4 (en) 2010-11-17
EP2101799A2 (en) 2009-09-23
HK1136202A1 (en) 2010-06-25
PT2101799E (pt) 2015-05-18
AU2007328265A1 (en) 2008-06-12
CA2672108C (en) 2016-10-25
JP2010511708A (ja) 2010-04-15
US8568803B2 (en) 2013-10-29
CA2672108A1 (en) 2008-06-12
AU2007328265B2 (en) 2014-02-27
US20070141181A1 (en) 2007-06-21

Similar Documents

Publication Publication Date Title
DK2101799T3 (da) Anvendelse af anaboliske midler, anti-kataboliske midler, antioxidantsmidler og analgetika til beskyttelse, behandling og gendannelse af bindevæv i mennesker og dyr
US8846118B2 (en) Use of anabolic agents, anti-catabolic agents, antioxidant agents and analgesics for protection, treatment and repair of connective tissues in humans and animals
US6797289B2 (en) Use of anabolic agents, anti-catabolic agents, antioxidant agents, and analgesics for protection, treatment and repair of connective tissues in humans and animals
US6451771B1 (en) Use of anabolic agents anti-catabolic agents and antioxidant agents for protection treatment and repair of connective tissues in humans and animals
AU764431B2 (en) Agents and methods for protection, treatment and repair of connective tissue
EP1762247A1 (en) The use of anabolic agents, anti-catabolic agents, antioxidant agents, and analgesics for protection, treatment and repair of connective tissue in humans and animals
AU2007200336B2 (en) Agents and methods for protection, treatment and repair of connective tissue
AU2004201991B2 (en) Agents and methods for protection, treatment and repair of connective tissue